John P. Griffin, E. A. Tolley, M. K. Zaman, H. Niell, F. Hammond Cole, D. Weiman
{"title":"Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis","authors":"John P. Griffin, E. A. Tolley, M. K. Zaman, H. Niell, F. Hammond Cole, D. Weiman","doi":"10.14312/2052-4994.2016-1","DOIUrl":null,"url":null,"abstract":"Objectives: To develop a clinical prediction model of contribution of chronic obstructive pulmonary disease (COPD) to the pathogenesis of lung cancer, by reporting the estimated prevalence and severity by GOLD criteria in a single-institution cohort of patients with newly diagnosed lung cancer. Primary objective was investigating the effects of impaired lung function with various histological cell types on crude survival, while considering the initial staging of disease extent. Materials & methods: A total of 441 patients, in this historical cohort from electronic medical records, completed spirometry prior to invasive diagnostic procedures and initial treatment of their lung cancer. All statistical analyses, including ANOVA and survival analysis, were performed using SAS version 9.1 software. Results: Estimated prevalence of COPD was 79.1% (95% confidence interval: 71.3%-82.9%). Lung function as measured by spirometry was a significant predictor of survival time in months (p.0001) both with and without adjusting for tumor-cell-type, age, and stage of disease. Median survival was similar (p0.32) and longer among those patients with normal pulmonary function, those with restrictive disease patterns, and those with COPD–GOLD-1 defects. Median survival was shortest among patients with COPD–GOLD-4 impairment (p0.001). Those patients with COPD–GOLD-2 and COPD-GOLD-3 impairment levels had intermediate survival times (p0.003). Conclusions: This investigation suggests that strategies for early detection and slowing the progression of COPD before the development of lung cancer might increase patient survival. As demonstrated in this study, the presence and severity of COPD in lung cancer patients is an independent predictor of survival time, different from the established staging of initial extent of disease.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"158 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14312/2052-4994.2016-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Objectives: To develop a clinical prediction model of contribution of chronic obstructive pulmonary disease (COPD) to the pathogenesis of lung cancer, by reporting the estimated prevalence and severity by GOLD criteria in a single-institution cohort of patients with newly diagnosed lung cancer. Primary objective was investigating the effects of impaired lung function with various histological cell types on crude survival, while considering the initial staging of disease extent. Materials & methods: A total of 441 patients, in this historical cohort from electronic medical records, completed spirometry prior to invasive diagnostic procedures and initial treatment of their lung cancer. All statistical analyses, including ANOVA and survival analysis, were performed using SAS version 9.1 software. Results: Estimated prevalence of COPD was 79.1% (95% confidence interval: 71.3%-82.9%). Lung function as measured by spirometry was a significant predictor of survival time in months (p.0001) both with and without adjusting for tumor-cell-type, age, and stage of disease. Median survival was similar (p0.32) and longer among those patients with normal pulmonary function, those with restrictive disease patterns, and those with COPD–GOLD-1 defects. Median survival was shortest among patients with COPD–GOLD-4 impairment (p0.001). Those patients with COPD–GOLD-2 and COPD-GOLD-3 impairment levels had intermediate survival times (p0.003). Conclusions: This investigation suggests that strategies for early detection and slowing the progression of COPD before the development of lung cancer might increase patient survival. As demonstrated in this study, the presence and severity of COPD in lung cancer patients is an independent predictor of survival time, different from the established staging of initial extent of disease.